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Colorectal cancer is one of the leading causes of mortality
due to malignancies worldwide. Its incidence in Eastern
Europe has been growing systematically, along with the
changes in life style adopted from the West. According to
the estimates, 1 out of 20 persons from Western Europe
will develop colorectal cancer, which accounts for about
200 000 new cases and 110000 deaths per annum [1, 2].
Unfortunately, only 50% of patients benefit from surgery
– due to the advanced stage of tumor at the time of
cancer diagnosis.
The 10-year survival rates for colorectal cancer
reported by the German Colorectal Cancer Group and by
the investigators from Scotland ranged from 20-63% in
patients undergoing resection. Significant differences
in survival point to the important role of surgeon’s
experience and quality assurance [3-5]. The last decade
has brought new management strategies to the treatment
of colorectal cancer, such as early diagnosis, improved
surgical standards, and the introduction of new models
of adjuvant chemo- and radiotherapy. Chemotherapy
significantly improves 5-year survival rates and the quality
of life in stage III colorectal cancer patients [6]. The
ongoing debates address the question of the role of
chemotherapy in stage II colorectal cancer and the use of
adjuvant chemotherapy [7].
The aim of this study was to analyze the prognostic
factors of colorectal cancer. 
Material and method
The analysis was performed on a group of 1332 patients with
histopathologically confirmed primary site colorectal cancer
operated in a single institution between the years 1984 and 2000.
The same study protocol was applied to all patients enrolled in
the study, and all of them were observed prospectively. The
group consisted of 576 women and 756 men, aged between
20 and 92 years. Of these 679 patients had a diagnosis of rectal
cancer, 620 – of colon cancer and in 33 cases we had confirmed
synchronic multifocal cancer in both localizations (Table I).
The stage of colorectal cancer was assessed according
to the TNM – UICC/AJCC system. The same pathologist
performed all histopathological examinations. Synchronic
multifocal cancer was classified according to the stage of the
most advanced lesion (Table II).
Curative resection (no residual tumor) was defined as R0;
R1 defined resections in which, microscopically, features of the
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M a t e r i a l  a n d  m e t h o d.  The analysis was based on a prospective study of 1332 patients operated on for primary
colorectal cancer at the 1st Department of General and GI Surgery in Cracow, Poland, between the years 1984 and 2000. The
same study protocol was applied to all patients included in the study.
R e s u l t s.  In the group of 1332 operated patients, 1262 underwent resective operations, and in the remaining 70 cases
palliative procedures, such as intestinal by-pass, colostomy or explorative surgery without tumor removal were performed. 96.3%
and 93.2% resective procedures were performed in the colon and the rectal cancer group, respectively. 
Five-year survival rates after resection were as follows (p<0.001): 86.3% for stage I colorectal cancer, 68.7% for stage II, 47.5%
for stage III, and 7% for stage IV.
Chemotherapy administered to patients with colorectal cancer prolonged both survival and the recurrence-free period. The
results were statistically significant in the groups with stage II (p=0.04) and III (p=0.05) colon cancer. In stage IV colon cancer
systemic chemotherapy prolonged patient survival, but failed to achieve statistical significance.
In stage II and III rectal cancer, systemic chemotherapy prolonged patient survival , however statistically significant differences
were found for stage III rectal cancer acc. to UICC/AJCC. In both colon and rectal cancers chemotherapy had no effect on
the recurrence-free period.
C o n c l u s i o n.  We conclude that extended lymphadenectomy and multivisceral resection is extremely important for the
curative outcome, also one cannot deny the importance of careful planning of the extent of colorectal surgery, including
decisions concerning the endpoints. Combined treatment of colorectal cancer improves long term results.
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residual tumor were left and R2 – resections with macro-
scopically discernible residual tumor.
All patients enrolled in the study were regularly followed-
up every 3-6 months until death. Follow-up was performed
according to the accepted study protocol, which included
physical examination, colorectal endoscopy, abdominal
ultrasonography and chest X-ray examinations. The obtained
results were used to calculate long-term survival and to assess
recurrence-free time (Table III).
S u r g e r y
Preoperative preparation of patients included large intestine
cleansing with osmotic agents, gastrointestinal tract decon-
tamination, and antibiotic prophylaxis. The tumor was removed
en block with the mesentery and the regional lymph nodes. For
left side colon tumors high (close to aorta) ligation of the inferior
mesenteric artery was performed.
Rectal cancer patients underwent either total mesorectal
excision (TME) or total transverse mesorectal excision (TTME)
with segmental sigmoid resection and ligation of the inferior
mesenteric artery. Between 1992 and 2000, the “extended
lymphadenectomy” (common iliac artery, periaortal, inferior
caval vein lymph nodes up to the lower border of the duodenal
wall) was performed for rectal cancer. For the colorectal
anastomosis either stapling or hand sutures were used.
A d j u v a n t  t h e r a p y
The applied models of chemotherapy for colorectal cancer were
modified basing on both own observations and on the results
reported by other authors (Figure 1).
We used systemic chemotherapy in 684 eligible patients
with colon cancer, stage II, III, and IV according to UICC/AJCC. 
Between 1984 and 1991, the patients were randomized
either to receive chemotherapy or to a no-chemotherapy group
(altogether 222 cases). In the subsequent period between 1992
and 2000 all eligible patients were randomized to receive
different types of chemotherapy. In the entire study group only
37 patients, who were not eligible or refused to give their consent
did not receive chemotherapy (Figure 1).
S t a t i s t i c a l  a n a l y s i s
Data was processed using descriptive statistic methods, and the
distributions of the analyzed variables were summarized in tables
and curves. Survival rates were presented acc. to the Kaplan-
Meier method and comparative analyses were conducted using
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Table I. Localization of colorectal cancer
Localization of CRC
n colon Rectum (multifocal) colon 
and rectum
Men 756 359 (47.5%) 373 (49.3%) 24 (3.2%)
Women 576 261 (45.3%) 306 (53.1%) 9 (1.6%)
Total 1332 620 (46.5%) 679 (51.0%) 33 (2.5%)
Table II. Staging of colorectal cancer (UICC/AJCC) acc to localization
Localization N Stage UICC/AJCC
I II III IV
11Colon 620
1
(17.9%) 212 (34.2%) 160 (25.8%) 137 (22.1%)
15Rectum 679
3
(22.5%) 176 (25.9%) 230 (33.9%) 120 (17.7%)
Multifocal colon and rectum 33 6 (18.2%) 10 (30.3%) 11 (33.3%) 6 (18.2%)
27Total 1332
0
(20.3%) 398 (29.9%) 401 (30.1%) 263 (19.7%)
Table III. Study protocol of colorectal cancer diagnostics and treatment
Rectoscopy, colonoscopy, USG
Preoperative diagnostics Manomethry, ERUS (rectal cancer), histopathology 
Psychological examination
Surgical treatment Resection or palliative surgical treatment 
Chemotherapy
Combined treatment Radiotherapy (preoperative)
Radiochemotherapy 
Physical examination (every 3 months)
Follow up Abdominal ultrasonography (every 6 months)
Chest X-ray , colonoscopy (every 12 months) 
Rectoscopy, ERUS, histopatholoy – as an option (every 12 months)
Figure 1. Chemotherapy models in colorectal cancer
the log-rank test. Also, multivariate statistical methods were
used with Cox’s proportional hazard model to correlate the
analyzed variables with the survival times.
Results
Of the1332 operated patients, 1262 underwent resection
or amputation (curative /R0/ or palliative /R1/R2/), and in
the remaining 70 cases we performed non-resective
procedures, such as intestinal by-pass, permanent
colostomy without tumor removal or explorative surgery
without tumor removal. The resection rate was 96.3%
for colon cancer and 93.2% for rectal cancer.
Multivisceral resections were performed in 95 (7.1%)
patients with T4 colon cancer invading other organs.
Multivisceral resections were more common in patients
with primary colon cancer (11.9%) than with rectal cancer
(4.3%). Involved organs included the small intestine, the
reproductive organs in female patients and the stomach.
Regardless of the resection type and tumor staging,
the radicality of surgery was assessed clinically and
verified pathologically using the R-classification of
Hermanek. Microscopically and macroscopically radical
resections were performed in 907 (68.1%) patients – 429
(69.2%) with colon cancer and 451 (66.4%) with rectal
cancer (Figure 2).
Macroscopically radical, but microscopically non-
radical (R1) resections were performed in 163 patients
(12.2%), and palliative (R2) resections in 262 patients
(19.7%). In the latter group residual cancer was left
beyond the removed organ, or it had metastasized to
distant organs or caused peritoneal dissemination.
Although other authors have reported a correlation
between tumor localization (colon vs. rectum) and long-
term treatment results, we did not observe such
a phenomenon. Long-term survival rates for the colon
cancer patients were higher (57.5%), as compared to
rectal cancer (55.5%), however they failed to achieve
statistical significance (Figure 3).
Synchronous cancer in the colon and rectum was
detected in 33 (2.55%) colon cancer patients. There
was a larger group of 128 (10.15%) patients with
detected colon polyps besides the primary cancer.
Polyps were removed endoscopically or the patients
underwent full-thickness rectal wall resection or intestinal
resection, depending on the result of histopathological
examination.
The most important prognostic factor determining
therapeutic outcome was the cancer stage, classified
according to the widely accepted UICC/AJCC system.
The use of the same staging system allowed to compare
our results with the results reported by other authors.
Five-year survival rates demonstrated significant diffe-
rences between the stage groups (p<0.001), and they
were: 86.3% for stage I colorectal cancer, 68.7% for
stage II, 47.5% for stage III, and 7% for stage IV
(Figure 4).
The prognostic role of colorectal cancer staging
was confirmed in the multivariate analysis. The most
important determinant of survival was the presence of
distant metastases (B=0.724 – strongest of all analyzed).
Less powerful, but also significant, was the local stage of
tumor (B=0.457). Among the anatomopathologic factors
we found two important, though less powerful – grading
(Table IV) and the presence of nodal metastases
(B=0.069) (Table V).
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Figure 2. Radicality of surgery verified pathologically using the R-
classification of Hermanek
Figure 3. 5-year survival in colon and rectal cancer acc. to extended lymphadenectomy (D 3) in the 2nd period
Table IV. Grading of colorectal cancer
n Grading
G 1 G 2 G 3
Men 756 596 (78.8%) 129 (17.1%) 31 (4.1%)
Women 576 443 (76.9%) 115 (20.0%) 18 (3.2%)
Total 1332 1039 (78.0%) 244 (18.3%) 49 (3.7%)
In the analyzed patients the extent of lympha-
denectomy had a confirmed effect on the long-term
results. The mean number of resected lymph nodes
increased from 8.62 in the years 1984-1991 to 19.17 in
the years 1991-2000. The patients subjected to extended
lymphadenectomy achieved longer survival (p<0.001) in
both the colon and the rectal cancer groups. The same
association was observed for the ratio of resected positive
nodes vs. the total number of resected lymph nodes,
where a higher rate negatively influenced survival
prognosis.
Chemotherapy administered to colorectal patients
prolonged long-term survival and recurrence-free time.
The results were statistically significant in stage II
(p=0.04) and stage III (p=0.05) colon cancer. In stage IV
colon cancer systemic chemotherapy prolonged patient
survival but failed to achieve statistical significance. In
stage II and III rectal cancer, systemic chemotherapy
prolonged long-term survival. In both colon and rectal
cancer chemotherapy had no effect on the recurrence-
free period (Figures 5, 6).
Discussion
The incidence of colorectal cancer has been increasing
worldwide, with no significant improvements observed
in the long-term treatment results.
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Figure 4. 5-year survival in colorectal cancer acc to the UICC/AJCC stage
Figure 5. 5-year survival acc. to systemic chemotherapy in stage II UICC/AJCC
Figure 6. 5-year survival acc. to systemic chemotherapy in stage III UICC/AJCC
Table V. Prognostic factors in long term results
of colorectal cancer treatment
Cox’s analysis p<0.0001
Factor B p
M (UICC/AJCC) 0.724845 0.000013
Extended lymphadenectomy (D3) 0.670740 0.000000
R (residual disease) 0.516972 0.000000
T (UICC/AJCC) 0.457743 0.000000
Chemotherapy 0.216628 0.044021
Metastatic lymph nodes 0.069224 0.000000
Number of resected lymph nodes 0.047083 0.000000
It is especially surprising in view of the quite
extensive knowledge regarding colorectal cancer patho-
genesis, long-term course of the disease, and the
availability of the various employed surgical techniques
[8].
Our prospective analysis of prognostic factors in
colorectal cancer was based on the results of surgical
treatment of patients operated in a single institution.
The same study protocol was applied in all cases and
histopathological examinations were performed by the
same experienced pathologist to avoid interpretation bias.
Until now, none of the medical centers in Poland
has opened a multicenter debate to set the guidelines for
the management of colorectal cancer, i.e. to follow the
example of the Royal College of Surgeons of England
[9] or the American Society of Clinical Oncology [10].
Treatment results of colorectal cancer in Poland are worse
than those reported in other European Union countries
or in the US. Despite the long-term experience with the
treatment of this disease there are still controversies as to
the surgical techniques, combined treatment or the extent
of surgery from minimally invasive to aggressive methods.
In the long-term studies launched in 1984 in our
Department, aimed at evaluating the correlations between
the surgical techniques and long-term colorectal cancer
treatment results we collected data which has allowed us
to draw conclusions as to the standards of colorectal
cancer treatment. A long period of observation and
a large study group allows to perform a reliable evaluation
of the changing results related to the applied treatment
models [11].
One of the most urgent problems in oncology is the
early detection of cancer. The stage of the disease at the
time of diagnosis and at the beginning of therapy
determines the final outcome [12]. At the time of
diagnosis only 50% of colorectal cancer patients can
undergo curative resections, while the remaining 50%
will not benefit from radical surgery. The differences in
the long-term survival figures necessitate the launch of
adequate colorectal cancer prevention programs and the
introduction of screening procedures capable of detecting
colorectal cancer at an early stage, or even at the
precancerous stage.
As for today the treatment results of stage I
colorectal cancer are satisfying, with 5-year survival
ranging from 95 to 98% [13]. However, the diagnosis of
colorectal cancer at such an early stage is possible in the
course of screening examinations or due to a better
understanding of preventive measures by practitioners,
who will refer patients for diagnostic tests. In many
countries worldwide the high incidence of colorectal
cancer has resulted in the launch of screening programs
with strong recommendations to cover the entire
populace over 50 years of age, if they report with clinical
symptoms or have a family history of cancer [14].
Beginning wit the year 1984, all colorectal cancer
patients treated at our institution had undergone pre- or
intraoperative colonoscopy to confirm the diagnosis,
tumor localization, and to detect synchronous lesions. In
5.3% of cases the diagnosis of synchronous lesions
changed the surgical tactics and extended resection.
Tumor localization within the colon is an inde-
pendent prognostic determinant of the therapeutic
outcome. The course of disease in colon cancer patients is
different than in the case of rectal cancer. Colon cancer
patients develop distant metastases and systemic spread
occurs more frequently than local recurrence, while rectal
cancer accounts for more regional recurrences [15, 16].
The relationship between survival and tumor localization
related to the pelvic peritoneum remains controversial
[17]. Despite the confirmed influence of tumor loca-
lization on long-term treatment results, we have failed
to find statistically significant differences regarding this
issue. Though 5-year survival of colon cancer patients
were higher, reaching 57.5%, no statistical significance
was found on comparison with rectal cancer (55.5%).
Tumor staging was comparable in both cancer
localizations, as was the number of R0 radical resections,
i.e. 66% for colon cancer and 62% for rectal cancer.
The strongest prognostic factor for long-term
survival and colorectal cancer recurrence-free time is the
tumor stage [18]. Our results are comparable with those
reported by other authors. Shelton and Wong report 5-
year survival in 74% of stage I colon cancer, 63% in stage
II, 46% in stage III and 6% in stage IV [19] – in our study
group this corresponds to 89.7% patients with stage I
disease, 70.5% in stage II, 48% in stage III and 9% in
stage IV. According to the same authors 5-year survival
for rectal cancer was 72% for stage I, 54% for stage II,
39% for stage III, and 7% for stage IV, while in our study
group we have observed 84.2% for stage I , 66% for stage
II, 43% for stage III, and 4% for stage IV. 
The strongest determinant of survival in colorectal
cancer patients was the presence of distant metastases
(M feature), then the local tumor stage (T feature), and
lymph nodes metastases (N). In stage III colorectal cancer
the presence of lymph node metastases was more
significant than the local tumor stage (B=0.116)
independently of the primary tumor localization. In stage
IV colorectal cancer, of all the anatomopathologic factors
only the M feature had prognostic value. Our results
correlate with those reported in the literature [20].
Lymph node metastases have a negative effect on
the long-term results [21-23]. Significantly more lymph
node metastases are observed in patients with tumors
penetrating through the muscularis propria of the
intestinal wall. In these cases both the metastases and
the intestinal wall infiltrations are independent prognostic
factors [24-26]. Long-term survival prognosis is usually
associated with the number of metastatic lymph nodes.
The comparative analyses of 5-year survival in 1016
patients with and without metastases reported by
Hermanek have reflected statistically significant
differences for 5-year survival – reaching 69% for the N0
group, 48% for N1 and 33% for N2 [16].
We found lymph nodes metastases in 401 (30.1%) of
the operated patients. The number of positive lymph
nodes was an independent prognostic factor of survival
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and of the recurrence-free time (p<0.003 and p<0.007).
However, the number of positive lymph nodes and their
relation to the number of all resected lymph nodes (colon
cancer p<0.01, rectal cancer p<0.003) was even more
significant for survival, which points to the important role
of lymphadenectomy, especially in stage III colorectal
cancer. 
Hojo et al. [27] found the differences in the survival
of patients with lymph nodes metastases N1 of 50-55%,
and from 22-28% for N2 colorectal cancer patients that is
sufficient argument for the extended lymphadenectomy. 
According to Hermanek radical resection with
simultaneous destruction of distant metastases to liver
or adjacent organs using cryo- or thermoablation methods
offers results identical with those of radical R0 resection.
We have also observed, that such treatment improves the
long-term results in stage IV colorectal cancer [28-30].
Extended lymphadenectomy has a significant
prognostic value. Although the improved long-term
survivals observed after extended lymphadenectomy,
which have been presented by the Japanese authors are
encouraging, still the observations of Enker et al. show
similar long-term survivals and rates of recurrence using
standard lymphadenectomy [31]. The benefits of
oncological resection are still under discussion. In the
analyzed group of patients we have observed a direct
correlation between extended lymphadenectomy and
survival in colon cancer patients by 11.6% and in rectal
cancer by 14.5% (p<0.001).
Standard treatment in colorectal surgery combines
surgery with chemo- and radiotherapy. In colon surgery
systemic chemotherapy already has an established role.
According to the NIH Consensus Conference, NCCTG,
ECOG, and IMPACT [32] the most relevant chemo-
therapeutic issue in regard to the outcome is the choice of
the apt chemotherapy model. According to Cunningham
and Findlay chemotherapy significantly prolongs survival
in colon cancer patients, and its role cannot, from now on,
be denied. Slevin postulates “No more nihilism in
adjuvant chemotherapy in colon cancer” [33, 34]. 
The analysis of prognostic factors in colorectal
cancer would not be complete without mentioning quality
assurance. The decisions made by the surgeons and their
skills have extreme influence on the therapeutic outcome.
Until the extent of the surgery or the need for en block
resection with adequate tissue margins becomes
a standard, the extent of lymphadenectomy, a significant
part of colorectal cancer surgery, will be still controversial. 
We conclude that extended lymphadenectomy is
extremely important for the curative outcome, apart from
the undeniable importance of careful planning of the
extent of colorectal surgery, including decisions con-
cerning the endpoints.
Professor Tadeusz Popiela MD, PhD
1st Department of General and GI Surgery
Jagiellonian University 
ul. Kopernika 40, 31-501 Kraków, Poland
mspopiel@cyf-kr.edu.pl
References
1. van Krieken JHJM, van de Velde C. Past, present and future perspectives
of colorectal cancer – on the brink of a new era? EJC 2002; 38: 855-7.
2. Pisani P, Parkin DM, Bray F et al. Estimates of the world-wide mortality
from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
3. McArdle CS, Hole D. Impact of variability among surgeons on post-
operative morbidity and mortality and ultimate survival. Br Med J 1991;
302: 1501-5.
4. Hermanek PJR, Wiebelth H, Riedl S et al. Long-term results of surgical
therapy of colon cancer; results of colorectal cancer study group.
Chirurgury 1994; 65: 287-97.
5. Hermanek PJR, Mansmann U, Staimmer DS et al. The German experien-
ces: the surgeon as a prognostic factor in colon and rectal cancer surgery.
Surg Oncol Clin North Am 2000; 9: 33-49.
6. Nornic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy of
primary chemotherapy in patients with advanced asymptomatic colorectal
cancer: a randomized trial. J Clin Oncol 1992; 10: 904-11.
7. Tebbutt NC et al. Systemic treatment of colorectal cancer. EJC 38, 2002,
1000-1015.
8. Bering CC, Squires TS, Tong T. Cancer statistics Ca – A. Cancer J Clin
1993; 43: 7-27.
9. Association of Coloproctology of Great Britain and Ireland, The Royal
Collage of Surgeons of England. Guidelines for the management of
Colorectal Cancer. 1996.
10. Desch CE, Benson AB III, Smith TJ et al. Recommended colorectal
cancer surveillance guidelines by the American Society of Clinical
Oncology. J Clin Oncol 1999; 17: 1312-21.
11. Popiela T. Wspó∏czesny algorytm diagnostyczno-terapeutyczny w raku
jelita grubego. Acta Endoscopica Pol 1998; 8, 105-107.
12. Kudo S, Kashida H, Nakajima T et al. Endoscopic diagnosis and
treatment of early colorectal kancer. World J Surg 1997; 21: 694-701.
13. Jagoditsch M et al. Long-term prognosis for colon cancer related to
consistent radical surgery: multivariative analysis of clinical, surgical and
pathologic variables. World J Surg 2000; 24: 1264-70.
14. Winawer SJ, Fletcher RH, Miller R et al. Colorectal cancer screening:
clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
15. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal
excision for rectal cancer. Lancet 1986; 1: 1479-82.
16. Hermanek P, Wiebelt H, Staimmer D et al. Prognostic factors of rectum
carcinoma – experience of the German Multicentre Study SGCRC.
German Study Group Colo-Rectal Carcinoma. Tumori 1995; 81 (3 suppl):
60-4.
17. Association of Coloproctology of Great Britain and Ireland. The Royal
Collage of Surgeons of England. Guidelines for the management of
Colorectal Cancer. 1996.
18. Walker J, Quirke P. Prognosis and response to therapy in colorectal
cancer. EJC 2002; 38 880-6.
19. Shelton A, Wong D. Colorectal cancer. In: Cameron J (ed.), Current
surgical therapy. 6-th ed. : Mosby; 1998, 217-28, St. Louis; USA.
20. Steinberg SM, Barkin JS, Kaplan RS et al. Prognostic indicators of colon
tumors: the Gastrointestinal Tumor Study Group experience. Cancer
1986; 57: 1866-70.
21. Glass R, Ritchie J, Thompson H et al. The results of surgical treatment of
cancer of the rectum by radical resection and extended abdomino-iliac
lymphadenectomy. Br J Surg 1985; 72: 599-601. 
22. Harnsberger JR, Vernava A et al. Radical abdominopelvic lympha-
denectomy: historic perspective and current role in the surgical
management of rectal cancer. Dis Colon Rectum 1994; 37: 73-87.
23. Kratochwil M, Richter P, Legutko J, Popiela T. Prognostic factors in local
and systemic recurrence after surgery of rectal carcinoma. 38 World
Congress of Surgery, International Surgical Week, ISW, Vienna 1999.
Abstr. Book nr. 226. s.57.
24. Kraemer M, Wiratkaup S, Seow-Choen F et al. Stratifying risk factors for
follow-up. A comparison of recurrent and nonrecurrent colorectal cancer.
Dis Colon Rectum 2001; 44: 815-21.
25. Moriya Y, Sugihara K, Akasu T et al. Importance of extended lympha-
denectomy with lateral node dissection for advanced rectal cancer. World
J Surg 1997; 21: 728-32.
26. Sitzler PJ, Seow-Choen F, Ho YH et al. Lymph node involvement and
tumor depth in rectal cancers: an analysis of 805 patients. Dis Colon
Rectum 1997; 40: 1472-6.
27. Hojo K, Koyama Y, Moriya Y. Lymphatic spread and its prognostic value
in patients with rectal cancer. Am J Surg 1982; 144: 350-4.
28. Coppa GF, Eng K, Ranson JH. et al. Hepatic resection for metastatic
colon and rectal cancer. Ann Surg 1985; 202: 203-8.
14
29. Elias D, Cavalcanti A, Sabourin JC et al. Resection of liver metastases
from colorectal cancer: the real impact of the surgical margin. Eur J Surg
Oncol 1998; 24: 174-9.
30. Jaeck D, Bachellier P, Guiguet M et al. Long-term survival following
resection of colorectal hepatic metastases. British J Surg 1997; 84: 977-80.
31. Enker WE, Thaler HT, Cranor ML et al. Total mesorectal excision in
the operative treatment of carcinoma of the rectum. J American College
Surg 1995; 181: 335-46.
32. Haller DG, ECOG. Phase III randomized comparison of adjuvant low-
dose CF/5-FU vs high-dose CF/5-FU vs low-dose CF/5-FU/LEV vs 5-
FU/LEV following curative resection in selected patients with dukes B2
and C carcinoma of the colon, EST-2288, Clinical trial, closed 07/30/1992.
33. Slevin M. Adjuvant treatment for colorectal cancer British Med J 1996;
312: 392-3.
34. Slevin ML, Papamichael D, Rougier P et al. Is there standard adjuvant
treatment for colon cancer? Eur J Cancer 1998; 34: 1652-63.
Paper received: 15 July 2005
Accepted: 3 August 2005
15
